The United States Food and Drug Administration (FDA) has granted accelerated approval to Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, for Balversa intended for the treatment of metastatic bladder cancer, it was reported yesterday.
The product is now indicated in the United States for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration called FGFR3 or FGFR2, and whose condition had progressed during or after being previously treated with platinum-containing chemotherapy. Accelerated approval was based on a phase 2 trial that featured 87 patients having locally advanced or metastatic bladder cancer, with FGFR3 or FGFR2 genetic alterations that had advanced after treatment with chemotherapy.
According to the company, continued approval for its drug for the indication is likely to be based on verification and description of clinical benefit in confirmatory trials. The US FDA stated that patients should be selected for treatment with the Janssen drug using a companion diagnostic device that it has approved.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML